|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
Technique shows how individual cancer cells react to drugs [UW Medicine]
|
|
|
|
|
|
The new technology combines improvements in labeling cell nuclei with advances in profiling what genes are expressed in each of millions of cells. This was accomplished at a single-cell resolution and in a cost-effective manner. They named the new screening method sci-Plex. In the Dec. 5 online edition of Science, the researchers report their proof-of-concept findings.
|
|
|
|
|
|
|
2. ETIOLOGIE
|
|
|
Hair Dye Isn’t Giving Everyone Cancer [Medium]
|
|
|
|
|
|
So, the headlines were wrong. There’s really no reason to believe that hair dyes directly cause breast cancer. There may be a risk associated with being the sort of person who dyes your hair a lot and getting a breast cancer diagnosis, but realistically that’s not the sort of thing you can change anyway.
|
|
|
|
|
|
|
2.13 ETIOLOGIE - NDMA
|
|
|
|
|
2.5 ETIOLOGIE - GÉNOME
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
Polygenic Modifiers of Pathogenic Genes May Refine Disease Risk Prediction [Genome Web]
|
|
|
|
|
|
"Much of the early work on particular polymorphisms modifying cancer risk has been available for a long time, so I don't actually understand why it was never introduced into clinical care," she said. "There were genetic testing laboratories that could have easily added those SNPs. They never did. I think they felt that there perhaps was not enough epidemiologic data or prospective data to do that."
|
|
|
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
Overcoming a Cancer Nemesis? KRAS Inhibitor Shows Promise in Early Trial [NCI]
|
|
|
|
|
|
While there is already a lot of excitement about the new drug, the number of patients who have been treated with it is relatively small, Dr. Durm cautioned. Another arm of the ongoing trial is testing AMG 510 in combination with an immune checkpoint inhibitor, and trials of AMG 510 in combination with other drugs are being planned, Dr. Durm said.
|
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
Bladder cancer gene therapy backed by Blackstone gets trial win [Biopharma Dive]
|
|
|
|
|
|
Nadofaragene firadenovec is an an adenovirus-based gene therapy encoding production of the immunity-stimulating protein interferon alfa-2b. Viral vectors containing the gene are administered by catheter once every three months into the bladder, where they are absorbed into cells in the organ's walls and begin stimulating interferon.
|
|
|
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
5.2 PHARMA
|
|
|
|
|
|
5.8 ASH
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7.3 DMP
|
|
|
|
6.8 COMMUNICATION
|
|
|